Please log in
to access more information


User name and Password not recognised

Home Page > The Company > Investors



About ACG Management

Created in 2000, as Viveris Management, ACG is a leading French third-party capital investment fund, and has developed a multi-regional approach dedicated to unlisted SMEs.
Supported by a strong investment team and spread across 7 locations in France, overseas and the Mediterranean (Morocco and Tunisia), the Company supports businesses, business leaders and potential buyers at all stages of development across the main sectors of the capital investment market: regional and national technology venture capital, capital development and transmission capital / leveraged buyout, with a majority or minority stake.
The Company currently manages a range of 35 investment vehicles in addition to the 46 it has had involvement in, including public funds (FCPI, FIP), and qualified investors (FCPR with simplified procedures). As of 30 June 2012, this represented €585M managed for 256 investments since it began. Since 1 January 2012, Viveris Management has belonged to the ACG, one of the main Capital Investment players, managing €1.5billion in assets through its management companies ACG Private Equity, Viveris Management, Sigma Gestion and IPSA.


About Bpifrance Large Venture

Bpifrance Large Venture is a €600m fund investing in healthcare, digital and green technology spaces. It funds high-growth companies with significant capital requirements for their international, industrial, or commercial development.
Large Venture is the next step in the financing cycle for venture-backed or revenue-generating companies, after early-stage VCs. Its goal is to help French national champions emerge, and help them scale globally.
Large Venture has a minimum investment size of €10 million (limited to 50% of the round), and only participates alongside professional investors. It has the ability to invest in both private and public markets.
Large Venture is a long-term, active minority investor and takes an active part in a company’s governance.


About Bpifrance and InnoBio

The public investment bank Bpifrance is the result of the merger of business funding and investment organizations OSEO, FSI, CDC Entreprises and FSI Regions. The aim of Bpifrance is to support businesses, (SMEs, mid-cap companies and larger entities of strategic importance to the French economy), from their seed capital stages up to stock market listing. They offer access to credit, collateral and equity funding. Bpifrance also provides assistance and enhanced support services for innovation, export and external growth.
InnoBio is a €173 million venture capital fund managed by Bpifrance, which is also an investor in the fund. Sanofi, GSK, Roche, Novartis, Pfizer, Lilly, Ipsen, Takeda and Boehringer-Ingelheim are among other investors. The main aim of the fund is to make equity investments in innovative companies providing technology, products and services for health care.


About Gimv

Gimv is a European investment company with over three decades of experience in private equity and venture capital. Gimv is listed on Euronext Brussels and currently manages around €1.8 billion (including investment partnerships) of investments in 50 portfolio companies. As a recognized market leader in selected investment platforms, Gimv dentifies entrepreneurial and innovative companies with high-growth potential and supports them in their transformation into market leaders. Gimv’s four investment platforms are: Consumer 2020, Health & Care, Smart Industries and Sustainable Cities. Each of these platforms works with a skilled and dedicated team across Gimv’s home markets of Benelux, France and Germany and can count on an extended international network of experts.


About Lundbeckfond Ventures

Lundbeckfond Ventures is a part of the asset management subsidiary of The Lundbeck Foundation which in addition to substantial financial assets has controlling ownerships in H.Lundbeck A/S, ALK-Abelló A/S and Falck A/S.
Lundbeckfond Ventures has an evergreen structure and invests around $60 million annually in life science companies. The Lundbeckfond Ventures team is located in Copenhagen, Denmark, and is active in both Europe and the USA.


About Mérieux Développement

Mérieux Développement is a Mérieux Institute investment company, a French industrial group holding that specialises in the healthcare field, with currently close to 10,000 employees around the world through its subsidiaries bioMérieux (NYSE Euronext, BIM), Silliker, Transgene (NYSE Euronext, TNG) and ABL.
Founded in 2009, Merieux Developpment has invested more than €200 million across 25 companies within the health and nutrition sectors. The pace and size of investments have increased significantly over the past 4 years, following the launch of a €150 million fund, Merieux Participation 2 and the expansion of the investment team in 2014.


About OTC Asset Management

Created in 2001, OTC Asset Management is a Capital Investment management company accredited by the AMF that manages over €430 million via its investment vehicles.
It uses its expertise to finance companies from all business sectors that make up the economic fabric of France, providing them with the funds required for their development and sustained growth. To date, OTC Asset Management has financed over 110 businesses that have doubled their turnover and increased their staff by 50%.


About Sham

Created in 1927, Sham is a mutual insurance company that specialiszes in the management of risks taken by the players in the health and medico-social fields. Sham is the first insurer with civil responsibility for medical liabilities in France. It has 5,947 members - individuals and corporate bodies - and manages €1.4 million worth of assets. Through its global risk management approach, Sham offers its members ranges of insurance and services that are completely adapted to their needs and specific requirements. Sham employs 270 people and in 2010 had a turnover of more than €290 million. Since 2007, Sham has been investing in dynamic businesses in the healthcare industry.


About Sofimac Partners

For over 30 years the Sofimac Partners group has specialised in the field of investment in non-listed companies in the South East of France. With a critical mass of assets worth €200 million, Sofimac Partners manage a portfolio of approximately one hundred lines and investments totaling approximately €10 million per year through different investment mediums. Its activities are structured around a capital-development/LBO in industry and services, and a technological center that mainly targets the healthcare/biotechnology fields. In 2008, it raised funds to support young biomedical technology businesses located in the Rhône-Alpes valley/Northern Italy region.